Welcome to our dedicated page for Ironwood Pharmaceuticals - news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals - stock.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a biopharmaceutical company dedicated to creating innovative medicines that significantly improve the lives of patients. Founded in 1998, Ironwood specializes in gastrointestinal (GI) therapeutics and has a strong focus on developing and commercializing treatments for chronic conditions of the GI tract.
The company's flagship product is a medicine designed for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This medicine, discovered and developed by Ironwood, is now fully commercialized and widely used to alleviate symptoms in patients, improving their quality of life.
Ironwood's research pipeline is robust, with multiple investigational medicines targeting both the upper and lower GI tract. The company leverages its expertise in gastrointestinal disorders and pharmacologic expertise in guanylate cyclases to develop new therapies that address unmet medical needs.
Beyond its core product, Ironwood is actively exploring new opportunities and expanding its portfolio through collaborative licenses, commercial agreements, and strategic acquisitions. These efforts aim to enhance the company's research, development, manufacturing, and marketing capabilities, thereby driving growth and innovation.
Recent achievements for Ironwood include the advancement of several clinical trials, promising data from ongoing research studies, and strategic partnerships aimed at enhancing product development and market reach. Financially, Ironwood continues to build value, achieving milestones that attract continued support from shareholders.
Ironwood Pharmaceuticals remains committed to its mission of making a difference for patients through the development of groundbreaking therapies. The company’s strong pipeline, dedicated team, and strategic initiatives position it as a leading player in the field of gastrointestinal therapeutics.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference scheduled for September 8, 2022, at 8:00 a.m. ET in Everett, MA. A live webcast will be available on the company's website, with a replay accessible for 14 days post-conference. Ironwood is renowned for its gastrointestinal healthcare focus, particularly with LINZESS®, a leading treatment for IBS-C and CIC. Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood aims to redefine GI care.
Ironwood Pharmaceuticals reported its Q2 2022 results, showcasing a 9% year-over-year growth in LINZESS prescription demand. Despite this, total revenues decreased to $97.2 million from $104.0 million in Q2 2021, with GAAP net income dropping significantly to $37 million from $391 million. The company completed its share repurchase program and repaid $120.7 million in convertible notes. Ironwood reiterated its guidance for 2022, projecting low single-digit U.S. LINZESS net sales growth and total revenue between $420 million and $430 million.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announces an investor update conference call on August 4, 2022, at 8:30 a.m. ET. Participants can join by calling (888) 330-2384 (U.S.) or (240) 789-2701 (international) with conference ID 4671230. The call will be recorded and available for replay starting at 11:30 a.m. ET the same day until August 18, 2022. Ironwood specializes in gastrointestinal healthcare, particularly with its LINZESS® treatment for IBS-C and CIC. More details can be found on their website.
Ironwood Pharmaceuticals (Nasdaq: IRWD) presented new findings at the 2022 Digestive Disease Week that suggest IW-3300 could manage abdominal pain in patients with disorders of gut-brain interaction. Current Phase I trials aim to explore this compound's potential for visceral pain conditions, including interstitial cystitis and endometriosis. The company also shared insights on the efficacy of linaclotide in treating IBS-C and functional constipation in pediatric patients, aiming to address the unmet needs in gastrointestinal diseases.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will showcase eight studies, including two oral presentations, at the Digestive Disease Week 2022 conference in San Diego from May 21 to May 24. One key study focuses on IW-3300's effect on chronic pelvic pain, while another analyzes linaclotide's impact on abdominal symptoms in IBS-C patients. CEO Tom McCourt will receive the ASGE President’s Award for his contributions to gastrointestinal endoscopy, highlighting Ironwood's ongoing commitment to GI health advancements.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported Q1 2022 results, highlighting an 11% year-over-year growth in LINZESS® (linaclotide) prescription demand. The U.S. net sales of LINZESS reached $232 million, marking an 8% increase year-over-year. Total revenue for the quarter was $98 million, with collaboration revenue from LINZESS at $94 million. The company achieved a GAAP net income of $39 million and ended the quarter with $593 million in cash. Ironwood remains focused on pipeline development and ongoing clinical trials for new GI treatments.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its first quarter 2022 investor update conference call on May 5, 2022, at 8:30 a.m. Eastern Time. Participants can join via phone or access a webcast from Ironwood's website. A replay will be available from 11:30 a.m. ET on the same day until May 19, 2022. Ironwood is known for its development of LINZESS®, a leading treatment for gastrointestinal diseases, aiming to improve care standards for patients with IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD), a leading gastrointestinal healthcare company, announced management presentations at two key investor conferences. The events include the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 a.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET. Live webcasts of these presentations will be available on Ironwood's website, with replays accessible for 14 days after the conferences. Ironwood is dedicated to advancing treatment for GI diseases, notably with its leading product LINZESS®.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported a strong financial performance for 2021, with total revenues reaching $414 million, driven largely by $400 million from U.S. LINZESS collaboration revenue. The company reported a GAAP net income of $528 million, boosted by a non-recurring tax benefit. Ironwood also made strategic advancements in its pipeline, initiating clinical studies for IW-3300 and CNP-104, targeting unmet medical needs in visceral pain and primary biliary cholangitis (PBC). The company ended 2021 with $620 million in cash and equivalents, positioning itself favorably for growth in 2022.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced an investor update conference call for its fourth quarter and full year 2021, scheduled for February 17, 2022, at 8:30 a.m. ET. Participants can dial in at (888) 330-2384 for US/Canada or (240) 789-2701 internationally, using conference ID 4671230. The call will be available for replay after 11:30 a.m. ET on the same day until March 3, 2022. Ironwood is focused on advancing treatments for gastrointestinal diseases, led by its product LINZESS®.
FAQ
What is the current stock price of Ironwood Pharmaceuticals - (IRWD)?
What is the market cap of Ironwood Pharmaceuticals - (IRWD)?
What does Ironwood Pharmaceuticals specialize in?
What is Ironwood's flagship product?
When was Ironwood Pharmaceuticals founded?
What are some of Ironwood's recent achievements?
How does Ironwood plan to expand its research and development capabilities?
What areas does Ironwood's research pipeline target?
What other conditions, besides IBS-C and CIC, is Ironwood working on?
How does Ironwood build value for its shareholders?
Where is Ironwood Pharmaceuticals listed?
What is the company's mission?
